Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTLA-2002 in Hereditary Angioedema
NCT05120830Phase 2Active, not recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Dec 2021
- Primary completion
- Apr 2024
- Modality
- CRISPR-Cas9, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
A Phase 2 trial of lonvoguran in hereditary angioedema (HAE), sponsored by Intellia Therapeutics. Started Dec 2021; status: active, not recruiting.
02
Drugs
lonvoguran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05120830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120830.